



HDPCR™ SARS CoV-2 Assay Inclusivity Analysis

Last updated: December 8, 2021

ChromaCode diligently performs *in silico* inclusivity analysis of its HDPCR SARS-CoV-2 Assay, routinely monitoring new and emerging SARS-CoV-2 sequences as they become available in the GISAID database.

As of the date of this publication, we can confirm that the ChromaCode HDPCR SARS-CoV-2 Assay is inclusive of the following:

- Alpha Variant, known as 20I/501.V1, VOC 202012/01, or B.1.1.7
- Beta Variant, known as 20H/501Y.V2 or B.1.351
- Gamma Variant, known as 20J/501Y.V3 or P.1
- Epsilon Variant, known as 21C/452R.V1 or B.1.427
- Epsilon Variant, known as 21C/452R.V1 or B.1.429
- Eta Variant, known as 20D/484K.V3 or B.1.525
- Iota Variant, known as 20F/253G.V1 or B.1.526
- Iota Variant, known as 20F or B.1.526.1
- The India Variant, known as B.1.617
- Kappa Variant, known as 21B/452R.V3 or B.1.617.1
- Delta Variant, known as 21A/478K.V1 or B.1.617.2
- The India Variant, known as B.1.617.3
- Zeta Variant, known as 20B/484K.V2 or P.2
- Omicron Variant, known as 21K or B.1.1.529

For a full list of updated *in silico* inclusivity study results, please see the most updated version of the HDPCR SARS-CoV-2 Assay Instructions for Use available at www.chromacode.com, through your instance of ChromaCode Cloud, or on www.fda.gov.

Support

For any questions or clarifications regarding this update, please contact ChromaCode Technical Support.

E-mail: technical.support@chromacode.com

Phone: +1 442-244-4370

